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The release of preloaded [3H]taurine from hippocampal slices from developing 7-day-old and young adult 3-month-old mice was
studied in a superfusion system in the absence of glucose. These hypoglycemic conditions enhanced the release at both ages, the
effect being markedly greater in developing mice. A depolarizing K+ concentration accentuated the release, which indicates that it
was partially mediated by exocytosis.The anion channel blockers were inhibitory, witnessing the contribution of ion channels. NO-
generating agents fomented the release as a sign of the participation of excitatory amino acid receptors.The other secondmessenger
systems were apparently less efficient. The much greater taurine release could be a reason for the well-known greater tolerance of
developing nervous tissue to lack of glucose.
1. Introduction
Hypoglycemia is a metabolic condition common during
development and may lead to severe neurological defects in
human infants. However, the effects of hypoglycemia on the
developing brain are still incompletely understood [1]. The
brain derivesmost of its energy from the oxidation of glucose,
but during development it also has an ability to utilize
alternative energy substrates which may offer protection
during hypoglycemia [2, 3]. On the other hand, poor reserves
of high-energy phosphates and a high metabolic rate may
predispose the developing brain to hypoglycemic injury [4,
5]. In the brain the hippocampus is the region most sensitive
to lack of oxygen and glucose. Energy deprivation leads to
neuronal cell death, caused primarily by excitotoxicity due to
excessive glutamate release [6, 7].
Taurine (2-aminoethanesulfonic acid) is present at high
concentrations in the brain. During ontogenic development
its concentration even exceeds that of the main excitatory
transmitter glutamate [8]. It increases membrane chloride
conductance, causing hyperpolarization and inhibiting neu-
ronal firing [9, 10]. Taurine also attenuates the excessive
neuronal accumulation of Ca2+, which predisposes cells
to damage [11] and prevents or reduces the glutamate-
induced elevation of intracellular Ca2+ [12] by inhibiting the
glutamate-induced release of Ca2+ from the internal pools
[13] and the glutamate-induced Ca2+ influx through L-, P/Q-,
andN-types of voltage-gatedCa2+ channels [14]. Taurine thus
regulates cytoplasmic and mitochondrial calcium homeosta-
sis [15] and in this manner protects neural cells against the
toxicity of excitatory amino acids in the hippocampus [16].
Cell-damaging conditions, including hypoglycemia, increase
the release of taurine [17, 18] together with that of excitatory
amino acid neurotransmitters. Our primary assumption is
that taurine release in the absence of an adequate supply of
glucose could protect neural cells from injury. In the present
studywe therefore examined the general properties of taurine
release in the hippocampus in hypoglycemia and how the
release is affected by ion channels, secondmessenger systems,
and adenosine receptors.
2. Materials and Methods
2.1. Materials. Developing (7-day-old) and young adult (3-
month-old) NMRI mice of both sexes were used in the
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experiments. All efforts were made to minimize both the
suffering and the number of the animals used. The exper-
iments conformed to the European Community Directive
(86/609/EEC) for ethical use of experimental animals and
were approved by the Committee of Tampere University
for animal experiments. [3H]Taurine (specific radioactivity
1.15 PBq/mol) was obtained from Amersham International,
Bristol, UK. The various effectors were purchased from the
Tocris Bioscience (Bristol, UK) or Sigma Aldrich (St. Louis,
MO).
2.2. Release Experiments. Coronal slices 0.4mm thick weigh-
ing 15–20mg were manually prepared from the mouse hip-
pocampus with a tissue slicer of Stadie-Riggs type. The slices
were immediately immersed in 5mL of oxygenated medium
and incubated with 0.01mM [3H]taurine (50MBq/L) at
37∘C for 30min under agitation.The standard Krebs-Ringer-
Hepesmediumcontained (inmmol/L)NaCl 127, KCl 5, CaCl
2
0.8, MgSO
4
1.3, Na
2
HPO
4
1.3, N-2-hydroxyethylpiperazine-
N󸀠-2-ethanesulphonic acid (Hepes) 15, NaOH 11, and D-
glucose 10 (pH 7.4). The slices were then transferred into
0.25mL cups and superfused with the above medium at a
rate of 0.25mL/min for 50min in a system in which freely
floating shaken slices were kept under a continuous flow
of oxygen in order to preserve their viability [19]. Hypo-
glycemic conditions were induced by omitting glucose from
the superfusion media. Potassium stimulation was applied
from 30 to 50min with 50mM K+. In our experimental
setup this K+ concentration has yielded the best and most
reproducible responses in GABA and taurine release [19].
This high K+ concentration may cause release not only from
neurons but from glial cells as well [20]. However, taurine
release is typically slow at onset and prolonged and high
K+ concentrations above those prevailing in vivo should be
used in in vitro experiments [21]. The different effectors
were added to the medium at the onset of superfusions, as
explained in the table legends. The superfusion medium was
pooled during the first 20min, whereafter 2min fractions
(0.5mL) were collected directly into small scintillation vials
with a fraction collector. After superfusion the slices were
weighed, homogenized in ice-cold 5% (w/v) trichloroacetic
acid solution, and centrifuged, and the clear supernatants
were used for scintillation counting. The effluent samples
were subjected to the same analyses.
2.3. Estimation of Efflux Rate Constants. Desaturation curves
of labeled taurine from the slices were plotted as a function
of time on the basis of the radioactivities remaining in
the slices after superfusion and recovered in the collected
superfusate fractions [19]. During superfusion the release
of labeled taurine originates initially from the extracellular
spaces in slices. This source is gradually exhausted during
the first 20min and the release subsequently occurs from the
intracellular pools.The efflux rate constants of taurine for the
time intervals of 20 to 30min (𝑘
1
, initial release phase) and
34–50min (𝑘
2
, later release phase) were computed as negative
slopes for the regression lines of the logarithmof radioactivity
remaining in the slices versus superfusion time. There were
no differences between the results frommale and femalemice
and the results from both sexes were therefore combined.
2.4. Statistical Analysis. The significance of the results was
analyzed with two-way analysis of variance (ANOVA) using
SPSS statistics, version 17.0, computer program. The analyses
were done by grouping the results according to the nature of
the effectors studied, potassium stimulation, chloride channel
blockers, NO-generating agents, adenosine agonists, and
second messengers. When significant effects were detected,
the post hoc Bonferroni test was applied to bring out the
differences between the sample means.They were considered
significant when the calculated 𝑝 values were less than 0.05
or 0.01.
3. Results
Hypoglycemia significantly enhanced taurine release in both
age groups. In adult 3-month-old mice the fractional release
rate constant in the presence of glucose inmediumwas for the
superfusion period of 34–50min (1.54±0.04) × 10−3 (𝑛 = 18)
and in the absence of glucose (1.93 ± 0.18) × 10−3, 𝑛 = 11,
significantly different at a level of p=0.042.Thehypoglycemia
effect wasmoremarked in 7-day-oldmice, the corresponding
constants being (0.38 ± 0.20) × 10−3, 𝑛 = 11, and (1.20 ± 0.12)
× 10−3, 𝑛 = 11, p = 0.000, respectively. Stimulation by 50mM
K+ enhanced the release in the absence of glucose (df = 3,
𝐹 = 23.007, 𝑝 = 0.000). The enhancements were 60 per cent
and 63 per cent in adult (𝑝 = 0.000) and developing (𝑝 =
0.001) mice, respectively (see Table 1).
The anion channel blockers generally inhibited the release
(df = 7, 𝐹 = 13.562, 𝑝 = 0.000). Of them, DIDS significantly
inhibited the K+-stimulated taurine release in both adult
(𝑝 = 0.013) and developing (𝑝 = 0.044) mice, being in
adult mice also effective on the unstimulated release (𝑝 =
0.047) (Table 1). SITS, the blocker of chloride transport, was
even more effective in all experimental situations (in adult
mice, unstimulated release 𝑝 = 0.11, stimulated release,
𝑝 = 0.035, and in developing mice the corresponding data
𝑝 = 0.016 and 𝑝 = 0.017). Another transport inhibitor
9-AC was not effective. All nitric oxide generators, SNAP,
SNP, and hydroxylamine, were strong stimulators in taurine
release in both adult (df = 7, 𝐹 = 32.190, 𝑝 = 0.000) and
developing (df = 7, 𝐹 = 13.732, 𝑝 = 0.000) mice and in both
the unstimulated and K+-stimulated release (Table 2). On the
other hand, all adenosine receptor agonists tested, CHA, R-
PIA and CGS 21680, and riluzole, which inhibits glutamate
release and GABA uptake, were without any effects (Table 3).
Of compounds involved in the second messenger sys-
tems, genistein, with its main known activity as a tyrosine
kinase inhibitor, was not effective during the period of 34–
50 (Table 4), whereas quinacrine, a nonselective inhibitor of
both monoamine oxidases A and B, inhibited the unstim-
ulated and K+-stimulated release in both age groups at all
stages of superfusion (df = 6, 𝐹 = 23.648, 𝑝 = 0.000).
The protein kinase C activator PMA only inhibited the
unstimulated release in adult mice (𝑝 = 0.036), whereas
the protein kinase inhibitor chelerythrine was not effective.
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Table 1: Effects of ion channel inhibitors on taurine release from hippocampal slices from 3-month-old and 7-day-old mice in hypoglycemia.
Effectors
Efflux rate constants (×10−3 min−1) ± SEM
3-month-old 7-day-old
𝑘
1
𝑘
2
𝑘
1
𝑘
2
Basal (control) 2.36 ± 0.11 (20) 1.93 ± 0.18 (11) 1.34 ± 0.08 (31) 1.20 ± 0.11 (11)
+50mMK+ (control) 2.92 ± 0.21 (10) 1.90 ± 0.10 (12)
DIDS 0.5mM 1.34 ± 0.15∗∗ (6) 1.31 ± 0.10∗ (4) 1.12 ± 0.14 (8) 1.16 ± 0.13 (4)
+50mMK+ 1.81 ± 0.12∗∗ (4) 1.45 ± 0.06∗ (4)
SITS 2.0mM 1.04 ± 0.07∗∗ (8) 0.93 ± 0.06∗∗ (4) 0.80 ± 0.09∗∗ (6) 0.62 ± 0.06∗∗ (4)
+50mMK+ 1.50 ± 0.21∗∗ (4) 0.90 ± 0.12∗∗ (4)
9-AC 0.2mM 2.67 ± 0.17 (5) 2.74 ± 0.49 (4) 1.82 ± 0.23 (8) 1.07 ± 0.09 (4)
+50mMK+ 3.53 ± 0.32 (4) 1.84 ± 0.10 (4)
The drugs were added at the beginning of superfusion and 50mMK+ at 30min. The results show the efflux rate constants ± SEM (×10−3 min−1) for
the time intervals of 20–30min (𝑘1) and 34–50min without the excess of K
+ or in the presence of 50mMK+ (𝑘2) with the number of independent
experiments in parenthesis. Abbreviations: DIDS, diisothiocyanostilbene-2󸀠2-disulphonate; SITS, 4-acetamido-4󸀠-isothiocyanostilbene-2󸀠2-disulphonate; 9-
AC, 9-anthracenecarboxylic acid. Significance of differences from the corresponding controls: ∗𝑝 < 0.05, ∗∗𝑝 < 0.01.
Table 2: Effects of nitric oxide generators on taurine release from hippocampal slices from 3-month-old and 7-day-oldmice in hypoglycemia.
Effectors
Efflux rate constants (×10−3min−1) ± SEM
3-month-old 7-day-old
𝑘
1
𝑘
2
𝑘
1
𝑘
2
Basal (control) 2.36 ± 0.11 (20) 1.93 ± 0.18 (11) 1.34 ± 0.08 (31) 1.20 ± 0.11 (11)
+50mMK+ (control) 2.92 ± 0.21 (10) 1.90 ± 0.10 (12)
SNAP 1.0mM 4.31 ± 0.22∗∗ (7) 5.44 ± 0.14∗∗ (4) 2.84 ± 0.11∗∗ (8) 2.17 ± 0.07∗∗ (4)
+50mMK+ 5.35 ± 0.15∗∗ (4) 2.34 ± 0.08∗∗ (4)
SNP 1.0mM 3.17 ± 0.13∗∗ (15) 4.23 ± 0.38∗∗ (8) 1.80 ± 0.21∗ (7) 1.65 ± 0.13∗ (4)
+50mMK+ 4.41 ± 0.77∗∗ (4) 1.98 ± 0.10∗∗ (4)
Hydroxylamine 5.0mM 5.16 ± 0.17∗∗ (7) 6.04 ± 0.76∗∗ (7) 3.82 ± 0.33∗∗ (8) 3.44 ± 0.16∗∗ (4)
+50mMK+ 7.03 ± 0.28∗∗ (4) 3.84 ± 0.10∗∗ (4)
The effectors were added at the beginning of superfusion and 50mMK+ at 30 min. The results show the efflux rate constants ± SEM (×10−3min−1) for the
time intervals of 20–30min (𝑘1) and 34–50min without the excess of K
+ or in the presence of 50mMK+ (𝑘2) with the number of independent experiments
in parenthesis. SNAP: S-nitroso-N-acetylpenicillamine; SNP: sodium nitroprusside. Significance of differences from the corresponding controls: ∗𝑝 < 0.05,
∗∗
𝑝 < 0.01.
Table 3: Effects of adenosine agonists and riluzole on taurine release from hippocampal slices from 3-month-old and 7-day-old mice in
hypoglycemia.
Effectors
Efflux rate constants (×10−3min−1) ± SEM
3-month-old 7-day-old
𝑘
1
𝑘
2
𝑘
1
𝑘
2
Basal (control) 2.36 ± 0.11 (20) 1.93 ± 0.18 (11) 1.34 ± 0.08 (31) 1.20 ± 0.11 (11)
+50mMK+ (control) 2.92 ± 0.21 (10) 1.90 ± 0.10 (12)
CHA 0.5mM 2.98 ± 0.12 (6) 1.85 ± 0.30 (6) 1.48 ± 0.07 (10) 1.11 ± 0.06 (7)
+50mMK+ 2.42 ± 0.27 (4) 2.00 ± 0.06 (4)
R-PIA 0.1mM 2.46 ± 0.17 (6) 1.92 ± 0.21 (6) 1.97 ± 0.19 (6) 1.41 ± 0.12 (4)
+50mMK+ 3.63 ± 0.51 (4) 2.12 ± 0.11 (4)
CGS 21680 10.0mM 2.59 ± 0.22 (4) 2.20 ± 0.20 (4) 1.75 ± 0.16 (6) 1.38 ± 0.20 (4)
+50mMK+ 3.44 ± 0.32 (4) 2.28 ± 0.11 (4)
Riluzole 0.1mM 2.47 ± 0.17 (7) 1.86 ± 0.27 (4) 1.86 ± 0.15∗ (6) 1.38 ± 0.10 (4)
+50mMK+ 2.50 ± 0.35 (4) 2.23 ± 0.15 (4)
The agonists were added at the beginning of superfusion and 50mMK+ at 30min. The results show the efflux rate constants ± SEM (×10−3min−1) for
the time intervals of 20–30min (𝑘1) and 34–50min without the excess of K
+ or in the presence of 50mMK+ (𝑘2) with the number of independent
experiments in parenthesis. CHA: N6-cyclohexyladenosine; R-PIA: (R(−)N6-(2-phenylisopropyl)adenosine; CGS 21680: 4-[2-[[6-amino-9-(N-ethyl-𝛽-D-
ribofuranuronamidosyl)-9H-purin-2-yl]amino]ethyl]benzenepropanoic acid hydrochloride. Significant difference from the control: ∗𝑝 < 0.05.
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Table 4: Effects of compounds involved in the second messenger systems on taurine release from mouse hippocampal slices in hypoxia.
Concentration (mM)
Efflux rate constants (×10−3min−1) ± SEM
3-month-old 7-day-old
𝑘
1
𝑘
2
𝑘
1
𝑘
2
Basal (control) 2.36 ± 0.11 (20) 1.93 ± 0.18 (11) 1.34 ± 0.08 (31) 1.20 ± 0.11 (11)
+50mMK+ (control) 2.92 ± 0.21 (10) 1.90 ± 0.10 (12)
Genistein 0.001 2.59 ± 0.13 (7) 2.06 ± 0.18 (7) 1.92 ± 0.16∗ (7) 1.44 ± 0.16 (4)
+50mMK+ 3.07 ± 0.25 (4) 2.27 ± 0.06 (4)
Quinacrine 0.01 1.20 ± 0.08∗∗ (7) 0.83 ± 0.05∗∗ (4) 0.75 ± 0.07∗∗ (8) 0.61 ± 0.06∗∗ (4)
+50mMK+ 1.12 ± 0.13∗∗ (4) 0.79 ± 0.05∗∗ (4)
PMA 0.00001 2.31 ± 0.20 (8) 1.77 ± 0.11 (4) 1.80 ± 0.15∗ (8) 1.33 ± 0.17 (4)
+50mMK+ 1.95 ± 0.17∗ (4) 1.85 ± 0.03 (4)
Chelerythrine 0.001 2.49 ± 0.17 (7) 2.07 ± 0.14 (4) 1.73 ± 0.18 (8) 1.53 ± 0.04 (4)
+50mMK+ 3.40 ± 0.51 (4) 2.01 ± 0.09 (4)
IBMX 1.0 1.85 ± 0.16 (8) 2.51 ± 0.29 (4) 1.99 ± 0.24 (6) 1.33 ± 0.11 (4)
+50mMK+ 2.70 ± 0.13 (4) 1.85 ± 0.03 (4)
RO 20-1724 0.2 3.46 ± 0.12∗∗ (8) 3.43 ± 0.15∗∗ (4) 1.96 ± 0.26 (7) 1.27 ± 0.17 (4)
+50mMK+ 4.56 ± 0.30∗∗ (4) 2.65 ± 0.33∗ (4)
Zaprinast 0.1 2.31 ± 0.15 (8) 2.00 ± 0.20 (8) 1.00 ± 0.13 (6) 0.66 ± 0.12∗ (4)
+50mMK+ 2.53 ± 0.06 (4) 2.04 ± 0.23 (4)
ODQ 0.01 2.51 ± 0.18 (7) 2.01 ± 0.13 (4) 1.50 ± 0.17 (8) 1.19 ± 0.08 (8)
+50mMK+ 2.50 ± 0.25 (4) 2.04 ± 0.06 (4)
Alloxan 5.0 2.81 ± 0.31 (7) 2.19 ± 0.06 (4) 1.70 ± 0.17 (6) 1.58 ± 0.25 (4)
+50mMK+ 3.13 ± 0.10 (4) 1.86 ± 0.07 (4)
The agonists were added at the beginning of the superfusion and 50 mM K+ at 30 min. The results show the efflux rate constants ± SEM (×10−3min−1) for the
time intervals of 20–30min (𝑘1) and for 34–50min without the excess of K
+ or in the presence of 50mMK+ (𝑘2) with the number of independent experiments
in parenthesis. PMA: 4𝛽-phorbol 12-myristate 13-acetate; IBMX: 3-isobutyl-1-methylxanthine; ODQ: 1H-[1,2,4]oxadiazolo[4,3]quinoxalin-1-one; RO 20-1724:
4-(3-butoxy-4-methoxyphenyl)-2-imidazolidone. Significance of differences from the corresponding controls: ∗𝑝 < 0.05, ∗∗𝑝 < 0.01.
The nonspecific inhibitor of cAMP and cGMP phosphodi-
esterases and the nonselective adenosine receptor antagonist
IBMX was not effective during the period of 34–50min. The
selective inhibitor of cGMP-insensitive phosphodiesterase,
type IV, RO 20-1724 enhanced both the unstimulated (𝑝 =
0.008) and stimulated (𝑝 = 0.005) release in adult mice and
also slightly the stimulated release (𝑝 = 0.038) in developing
mice (Table 4). The selective inhibitor of cGMP-specific
phosphodiesterases V andVI (PDE5/6) and the agonist at the
G protein-coupled receptor 35 zaprinast significantly (𝑝 =
0.035) reduced the unstimulated release in 7-day-old mice,
whereas ODQ, the potent and selective inhibitor of NO-
sensitive guanylyl cyclase, was without effect. Alloxan, the
unspecific inhibitor of adenylyl cyclases, was likewise not
effective during the period of 34–50min.
4. Discussion
The present results show taurine release to be enhanced
in hypoxia at both ages studied, the effect being more
pronounced in the developing hippocampus. The release is
largely mediated by anion channels, since the anion channel
inhibitors markedly reduced it. The nitric acid generators
strongly stimulated the release. The effects of the second
messenger systemweremore variable.These actionswere also
in many cases different in adult and developing mice.
The enhancement could be due to several mechanisms,
including Ca2+-dependent exocytosis, Ca2+-independent
release via reversal of carrier-mediated uptake, indiscrim-
inate opening of ion channels which allow the passage
of taurine molecules, or leakage through damaged plasma
membranes. Depolarization by K+-stimulation was now able
to further potentiate taurine release at both ages under
hypoglycemia. This may signify release via exocytosis, which
is also preserved in hippocampal sliceswhen they are exposed
to even more drastic cell-damaging conditions such as
ischemia (the absence of glucose and oxygen atmosphere)
[17, 18]. In developing mice taurine release in the absence
of glucose is approximately the same as in the presence
of nitrogen atmosphere without glucose, whereas in adults
these ischemic conditions have had even more impact [18].
Both neurons and glial cells have been shown to contain
taurine [22], and thus only a part of the released taurine
may originate fromneurons. K+ stimulation of taurine release
has also been shown to be associated with cell swelling [23].
Indeed, the volume-regulated anion channelsmay contribute,
together with the reversed function of astrocytic glutamate
transporters, up to 80 per cent of the total release of taurine
and excitatory amino acids in global cerebral ischemia in rats
[24].
Intracellular swelling activates stretch-sensitive (volume-
regulated) ion channels and is accompanied by the release
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of both inorganic and organic osmolytes, including taurine
[25]. For instance, the volume-regulated anion channels have
been shown to be the predominant contributors to the release
of excitatory amino acids in the ischemic cortical penum-
bra [26]. The swelling-induced increase in taurine release
is a diffusional process without any carrier involvement
[27].
In both the developing and adult hippocampus the presy-
naptically acting ionotropic glutamate agonists significantly
increase the release of taurine in a receptor-mediatedmanner
[28, 29]. For instance, of the ionotropic receptors, NMDA
receptor activation in particular has been assumed to play
a central role in hypoglycemia-induced glutamate release
[30]. Activation of NMDA receptors allows Ca2+ to enter
the cells. NO synthase is a Ca2+-dependent enzyme [31],
being activated in the presence of Ca2+ and then producing
NO. NO stimulates soluble guanylate cyclase and in this
manner foments the production of 3󸀠,5󸀠-cyclic guanosine
monophosphate [32], which enhances taurine release [33].
The present activatory effect of the NO generators studied
is in concert with this sequence of events. NO also regulates
neuronal activity by activating calcium-dependent potassium
channels [34, 35]. NO can be the endogenous opener of leak
K+ channels in the hippocampus as shown in basal forebrain
cholinergic neurons [36]. The increase in extracellular K+
enhances taurine release. The NO donors did not markedly
foment the K+-evoked release now.The effect was apparently
already maximal at the K+ concentration used in this study.
NO produced by an exogenous NO donor has been
shown to block both tetrodotoxin-sensitive and tetrodotoxin-
resistant Na+ currents in baroreceptor neurons [37] and
NO to block different Na+ channels in baroreceptor neu-
rons [38]. In contrast, NO donors SNP and SNAP have
significantly increased the mean persistent current in excised
inside-out patches from cultured hippocampal neurons [39].
Such results suggest that, depending on cell type, NO may
modulate Na+ currents differently. Taurine efflux has been
shown to be dependent on the presence of both Na+ and
Cl− ions [40]. The reduction of release by the Cl− channel
antagonists SITS and DIDS indicates that the release may
also occur through anion channels, similar to the volume-
sensitive taurine release in astrocytes and neurons [41, 42].
The present attenuating effect of quinacrine on the release
is furthermore in line with this assumption since quinacrine
has been shown to inhibit the hypotonically induced whole
cell Cl− currents in human submandibular gland (HSG) cells
[43].
The various second messengers exerted less pronounced
effects on taurine release. In keeping with this the effects
of different metabotropic glutamate receptor agonists and
antagonists have also not been particularly effective in taurine
release in the hippocampus [44]. The presynaptic adenosine
receptors, particularly of the A1 class, are known to regulate
neurotransmitter release [45]. The A1 receptors have also
enhanced taurine release in the adult hippocampus, but only
when it was subjected to K+ stimulation in ischemia [46].
In the present study the nonspecific antagonist of adenosine
receptors likewise exhibited only minor effects.
5. Conclusions
The release of taurine in the hypoglycemic hippocampus
of both young and adult mice appears to be a complex
process mediated by several different mechanisms, such as
exocytosis, carrier reversal, diffusion via ion channels, and
probably leakage through partially damaged cell membranes.
Hypoglycemia also evokes the release of excitatory amino
acids [6, 18]. Glutamate release overactivates its receptors and
functions as an excitotoxic agent. There is a rationale here in
that the activation of excitatory amino acid receptors causes a
concomitant increase in taurine release. Taurine is inhibitory
in nature and counteracts this excessive excitation. In the
developing brain taurine release is much larger in magnitude
than in the adult brain, which could be a reason for the well-
known greater tolerance of developing nervous tissue to lack
of glucose.
Abbreviations
9-AC: 9-Antracenecarboxylate
AIDA: (RS)-1-Aminoindan-1,5-
dicarboxylate
AMPA: 2-Amino-3-hydroxy-5-methyl-4-
isoxazolepropionate
2R,4R-APDC: (2R,4R)-4-Aminopyrrolidine-2,4-
dicarboxylate
cAMP: Cyclic adenosine monophosphate
ATPase: Adenosine triphosphatase
cGMP: Cyclic guanosine monophosphate
CGS 21680: 4-[2-[[6-Amino-9-(N-ethyl-𝛽-D-
ribofuranuronamidosyl)-9H-
purin-2-
yl]amino]ethyl]benzenepropanoic
acid hydrochloride
CHA: N6-Cyclohexyladenosine
DHPG: (S)-3,5-Dihydroxyphenylglycine
DIDS: Diisothiocyanostilbene-2,2󸀠-
disulphonate
DMPX: 3,7-Dimethyl-1-propargylxanthine
EDTA: Ethylenediaminetetraacetate
EGLU: (2S)-2-Cyclopropyl-4-
phosphonophenylglycine
GABA: 𝛾-Aminobutyrate
GAT: GABA transporter
HA: Hydroxylamine
Hepes: N-2-Hydroxyethylpiperazine-N󸀠-
2-ethanesulphonic
acid
IBMX: 3-Isobutyl-1-methylxanthine
L-AP4: L(+)-2-Amino-4-
phosphonobutyrate
L-NAME: N6-Nitro-L-argininemethylester
L-SOP: O-Phospho-L-serine
MK-801 (dizocilpine): (5S,10R)-(+)-Methyl-10,11-
dihydro-5H-
dibenzo(a,d)cyclohepten-5,10-
amine
6 Journal of Amino Acids
NBQX: 2,3-Dioxo-6-nitro-1,2,3,4-
tetrahydrobenzo[f]quinoxaline-7-
sulfonamide
NMDA: N-Methyl-D-aspartate
ODQ: 1H-(1,2,4)Oxadiazolo(4,3-a)quinoxalin-1-
one
PDE: Phosphodiesterase
PMA: 4𝛽-Phorbol 12-myristate 13-acetate
PKC: Protein kinase C
RO 20-1724: 4-(3-Butoxy-4-methoxyphenyl)-2-
imidazolidone
R-PIA: R(−)N6-(2-Phenylisopropyl)adenosine
SITS: 4-Acetamido-4󸀠-isothiocyanostilbene-
2,2󸀠-disulphonate
SNAP: S-Nitroso-N-acetylpenicillamine
SNP: Sodium nitroprusside.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
The skillful technical assistance of Mrs. Irma Rantamaa and
the invaluable help of Dr. Sakari Oja in statistical analyses are
gratefully acknowledged.
References
[1] M. Cornblath, J. M. Hawdon, A. F. Williams et al., “Controver-
sies regarding definition of neonatal hypoglycemia: suggested
operational thresholds,” Pediatrics, vol. 105, no. 5, pp. 1141–1145,
2000.
[2] A. Nehlig and A. P. de Vasconcelos, “Glucose and ketone
body utilization by the brain of neonatal rats,” Progress in
Neurobiology, vol. 40, no. 2, pp. 163–221, 1993.
[3] R. C. Vannucci and S. J. Vannucci, “Hypoglycemic brain injury,”
Seminars in Neurobiology, vol. 6, pp. 73–79, 2001.
[4] J. E. McGowan and J. M. Perlman, “Glucose management
during and after intensive delivery room resuscitation,” Clinics
in Perinatology, vol. 33, no. 1, pp. 183–196, 2006.
[5] C. M. Burns, M. A. Rutherford, J. P. Boardman, and F. M.
Cowan, “Patterns of cerebral injury and neurodevelopmental
outcomes after symptomatic neonatal hypoglycemia,” Pedi-
atrics, vol. 122, no. 1, pp. 65–74, 2008.
[6] M. Szatkowski and D. Attwell, “Triggering and execution of
neuronal death in brain ischaemia: two phases of glutamate
release by different mechanisms,” Trends in Neurosciences, vol.
17, no. 9, pp. 359–365, 1994.
[7] J.-M. Lee, G. J. Zipfel, and D.W. Choi, “The changing landscape
of ischaemic brain injurymechanisms,”Nature, vol. 399, pp.A7–
A14, 1999.
[8] P. Saransaari and S. S. Oja, “Taurine and neural cell damage,”
Amino Acids, vol. 19, no. 3-4, pp. 509–526, 2000.
[9] S. S. Oja, P. Kontro, and P. La¨hdesma¨ki, “Amino acids as
inhibitory neurotransmitters,” Progress in Pharmacology, vol. 1,
no. 3, pp. 1–119, 1977.
[10] S. Oja, E. R. Korpi, and P. Saransaari, “Iodification of chloride
flux across brain membranes by inhibitory amino acids in
developing and adult mice,”Neurochemical Research, vol. 15, no.
8, pp. 797–804, 1990.
[11] P. Kontro and S. S. Oja, “Effects of taurine on the influx and
efflux of calcium in brain slices of adult and developing mice,”
International Journal of Neuroscience, vol. 38, no. 1-2, pp. 103–
109, 1988.
[12] W. Q. Chen, H. Jin, M. Nguyen et al., “Role of taurine in
regulation of intracellular calcium level and neuroprotective
function in cultured neurons,” Journal of Neuroscience Research,
vol. 66, no. 4, pp. 612–619, 2001.
[13] J.-Y. Wu, W. Chen, X. W. Tang et al., “Mode of action of taurine
and regulation dynamics of its synthesis in the CNS,” Advances
in ExperimentalMedicine and Biology, vol. 483, pp. 35–44, 2000.
[14] H.Wu,Y. Jin, J.Wei,H. Jin,D. Sha, and J.-Y.Wu, “Mode of action
of taurine as a neuroprotector,” Brain Research, vol. 1038, no. 2,
pp. 123–131, 2005.
[15] A. El Idrissi and E. Trenkner, “Taurine regulates mitochondrial
calcium homeostasis,” Advances in Experimental Medicine and
Biology, vol. 526, pp. 527–536, 2003.
[16] E. D. French, A. Vezzani, W. O. Whetsell Jr., and R. Schwarcz,
“Anti-excitotoxic actions of taurine in the rat hippocampus
studied in vivo and in vitro,”Advances in ExperimentalMedicine
and Biology, vol. 203, pp. 349–362, 1986.
[17] P. Saransaari and S. S. Oja, “Enhanced taurine release in cell-
damaging conditions in the developing and ageing mouse
hippocampus,” Neuroscience, vol. 79, no. 3, pp. 847–854, 1997.
[18] P. Saransaari and S. S. Oja, “Release of endogenous glutamate,
aspartate, GABA, and taurine from hippocampal slices from
adult and developing mice under cell-damaging conditions,”
Neurochemical Research, vol. 23, no. 4, pp. 563–570, 1998.
[19] P. Kontro and S. S. Oja, “Taurine andGABA release frommouse
cerebral cortex slices: potassium stimulation releases more
taurine than GABA from developing brain,” Developmental
Brain Research, vol. 37, no. 1-2, pp. 277–291, 1987.
[20] G. Levi, “Release of putative transmitter amino acids,” in
Handbook of Neurochemistry, A. Lajtha, Ed., vol. 6, pp. 463–509,
Plenum Press, New York, NY, USA, 2nd edition, 1984.
[21] P. Saransaari and S. S. Oja, “Release of GABA and taurine from
brain slices,” Progress in Neurobiology, vol. 38, no. 5, pp. 455–
482, 1992.
[22] S. S. Oja and P. Saransaari, “Taurine,” in Handbook of Neuro-
chemistry and Molecular Neurobiology, S. S. Oja, P. Saransaari,
and A. Schousboe, Eds., vol. 6, pp. 155–206, Springer, NewYork,
NY, USA, 3rd edition, 2007.
[23] A. Schousboe, J. Mora´n, and H. Pasantes-Morales, “Potassium-
stimulated release of taurine from cultured cerebellar granule
neurons is associated with cell swelling,” Journal of Neuroscience
Research, vol. 27, no. 1, pp. 71–77, 1990.
[24] H. K. Kimelberg, N. B. Nestor, and P. J. Feustel, “Inhibition
of release of taurine and excitatory amino acids in ischemia
and neuroprotection,”Neurochemical Research, vol. 29, no. 1, pp.
267–274, 2004.
[25] H. Pasantes-Morales, S. Alavez, R. S. Olea, and J. Mora´n,
“Contribution of organic and inorganic osmolytes to volume
regulation in rat brain cells in culture,”Neurochemical Research,
vol. 18, no. 4, pp. 445–452, 1993.
[26] P. J. Feustel, Y. Jin, and H. K. Kimelberg, “Volume-regulated
anion channels are the predominant contributors to release
of excitatory amino acids in the ischemic cortical penumbra,”
Stroke, vol. 35, no. 5, pp. 1164–1168, 2004.
Journal of Amino Acids 7
[27] R. Sa´nchez-Olea, C. Pen˜a, J. Mora´n, and H. Pasantes-Morales,
“Inhibition of volume regulation and efflux of osmoregulatory
amino acids by blockers of Cl− transport in cultured astrocytes,”
Neuroscience Letters, vol. 156, no. 1-2, pp. 141–144, 1993.
[28] T. Smirnova, J. Stinnakre, and J. Mallet, “Characterization of a
presynaptic glutamate receptor,” Science, vol. 262, no. 5132, pp.
430–433, 1993.
[29] S. S. Oja and P. Saransaari, “Modulation of taurine release
in glucose-free media by glutamate receptors in hippocampal
slices from developing and adult mice,” Amino Acids, vol. 44,
no. 2, pp. 533–542, 2013.
[30] R. N. Ichord, M. V. Johnston, and R. J. Traystman, “MK801
decreases glutamate release and oxidative metabolism during
hypoglycemic coma in piglets,” Developmental Brain Research,
vol. 128, no. 2, pp. 139–148, 2001.
[31] D. S. Bredt, C. D. Ferris, and S. H. Snyder, “Nitric oxide synthase
regulatory sites. Phosphorylation by cyclic AMP-dependent
protein kinase, protein kinase C, and calcium/calmodulin
protein kinase; identification of flavin and calmodulin binding
sites,” The Journal of Biological Chemistry, vol. 267, no. 16, pp.
10976–10981, 1992.
[32] E. M. Schuman and D. V. Madison, “Nitric oxide and synaptic
function,” Annual Review of Neuroscience, vol. 17, pp. 153–183,
1994.
[33] P. Saransaari and S. S. Oja, “Taurine release in the developing
and adultmouse hippocampus: involvement of cyclic guanosine
monophosphate,” Neurochemical Research, vol. 27, no. 1-2, pp.
15–20, 2002.
[34] V. M. Bolotina, S. Najibi, J. J. Palacino, P. J. Pagano, and R.
A. Cohen, “Nitric oxide directly activates calcium-dependent
potassium channels in vascular smooth muscle,” Nature, vol.
368, no. 6474, pp. 850–853, 1994.
[35] L. R. Zhong, S. Estes, L. Artinian, and V. Rehder, “Nitric oxide
regulates neuronal activity via calcium-activated potassium
channels,” PLoS ONE, vol. 8, no. 11, Article ID e78727, 2013.
[36] Y. Kang, Y. Dempo, A. Ohashi et al., “Nitric oxide activates
leak K+ currents in the presumed cholinergic neuron of basal
forebrain,” Journal of Neurophysiology, vol. 98, no. 6, pp. 3397–
3410, 2007.
[37] Z. Li,M.W. Chapleau, J. N. Bates, K. Bielefeldt, H.-C. Lee, and F.
M. Abboud, “Nitric oxide as an autocrine regulator of sodium
currents in baroreceptor neurons,” Neuron, vol. 20, no. 5, pp.
1039–1049, 1998.
[38] M. Renganathan, T. R. Cummins, and S. G. Waxman, “Nitric
oxide blocks fast, slow, and persistent Na+ channels in C-type
DRG neurons by S-nitrosylation,” Journal of Neurophysiology,
vol. 87, no. 2, pp. 761–775, 2002.
[39] A. K. M. Hammarstrom and P. W. Gage, “Nitric oxide increases
persistent sodium current in rat hippocampal neurons,” Journal
of Physiology, vol. 520, part 2, pp. 451–461, 1999.
[40] X. Han, A. B. Patters, D. P. Jones, I. Zelikovic, and R. W.
Chesney, “The taurine transporter: mechanisms of regulation,”
Acta Physiologica, vol. 187, no. 1-2, pp. 61–73, 2006.
[41] H. K. Kimelberg, S. K. Goderie, S. Higman, S. Pang, and R. A.
Waniewski, “Swelling-induced release of glutamate, aspartate,
and taurine from astrocyte cultures,” The Journal of Neuro-
science, vol. 10, no. 5, pp. 1583–1591, 1990.
[42] A. Schousboe, R. Sanchez-Olea, J. Mora´n, and H. Pasantes-
Morales, “Hyposmolarity-induced taurine release in cerebellar
granule cells is associated with diffusion and not with high-
affinity transport,” Journal of Neuroscience Research, vol. 30, no.
4, pp. 661–665, 1991.
[43] S. Fatherazi, K. T. Izutsu, R. B. Wellner, and C. M. Belton,
“Hypotonically activated chloride current inHSG cells,” Journal
of Membrane Biology, vol. 142, no. 2, pp. 181–193, 1994.
[44] P. Saransaari and S. S. Oja, “Involvement of metabotropic glu-
tamate receptors in taurine release in the adult and developing
mouse hippocampus,” Amino Acids, vol. 16, no. 2, pp. 165–179,
1999.
[45] R. A. Cunha, “Adenosine as a neuromodulator and as a homeo-
static regulator in the nervous system: different roles, different
sources and different receptors,” Neurochemistry International,
vol. 38, no. 2, pp. 107–125, 2001.
[46] P. Saransaari and S. S. Oja, “Interactions of taurine and adeno-
sine in the mouse hippocampus in normoxia and ischemia,”
Advances in Experimental Medicine and Biology, vol. 526, pp.
445–451, 2003.
Submit your manuscripts at
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Anatomy 
Research International
Peptides
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation 
http://www.hindawi.com
 International Journal of
Volume 2014
Zoology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Molecular Biology 
International 
Genomics
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Bioinformatics
Advances in
Marine Biology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Signal Transduction
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Evolutionary Biology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Biochemistry 
Research International
Archaea
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Genetics 
Research International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Advances in
Virolog y
Hindawi Publishing Corporation
http://www.hindawi.com
Nucleic Acids
Journal of
Volume 2014
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Enzyme 
Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
International Journal of
Microbiology
